Table 3 Build up phase with administration of omalizumab
From: Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab
Week no. | Premedication | Omalizumab (mg) | HB venom cumulative dose (mcg) | Adverse reactions |
|---|---|---|---|---|
1 | 150 | |||
3 | 300 | |||
4 | Terfenadine | 4.11 | None | |
5 | Terfenadine | 300 | 10 | Cough and dysphagia |
6 | Hydrocortisone Ranitidine Cetirizine | 20 | None | |
7 | Hydrocortisone Ranitidine Cetirizine | 300 | 30 | Ocular and palmar itching |
8 | 300 | |||
9 | Hydrocortisone Ranitidine Cetirizine | 45 | None | |
10 | Hydrocortisone Ranitidine Cetirizine | 300 | 60 | None |
11 | Hydrocortisone Ranitidine Cetirizine | 80 | None | |
12 | 300 | |||
13 | Hydrocortisone Ranitidine Cetirizine | 100 | None | |
14 | Hydrocortisone Ranitidine Cetirizine | 300 | 130 | None |
15 | Hydrocortisone Ranitidine Cetirizine | 170 | None | |
16 | Hydrocortisone Ranitidine Cetirizine | 300 | 200 | None |